Alberico L. Catapano

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 529 publications

Evaluating enlicitide decanoate: first oral PCSK9 inhibitor for the treatment of adults with hypercholesterolemia.

Evaluating enlicitide decanoate: first oral PCSK9 inhibitor for the treatment of adults with hypercholesterolemia.

Journal: Expert opinion on pharmacotherapy

Published: September 08, 2026

Global Burden of Elevated LDL-C: Findings From the Global Burden of Disease Study 2023.

Global Burden of Elevated LDL-C: Findings From the Global Burden of Disease Study 2023.

Journal: JAMA

Published: July 29, 2026

Low-density lipoprotein cholesterol management and goal attainment at 1 year in patients with diabetes, pre-diabetes and normoglycaemia: results from the European, prospective, observational SANTORINI study.

Low-density lipoprotein cholesterol management and goal attainment at 1 year in patients with diabetes, pre-diabetes and normoglycaemia: results from the European, prospective, observational SANTORINI study.

Journal: BMJ open

Published: June 29, 2026

Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid.

Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid.

Journal: Journal of the American Heart Association

Published: June 23, 2026

Lipids and abdominal aortic aneurysm: from pathophysiology to therapy. A call to action from the Italian Society for the Study of Atherosclerosis and the Italian Society for Angiology and Vascular Medicine.

Lipids and abdominal aortic aneurysm: from pathophysiology to therapy. A call to action from the Italian Society for the Study of Atherosclerosis and the Italian Society for Angiology and Vascular Medicine.

Journal: Nutrition, metabolism, and cardiovascular diseases : NMCD

Published: June 16, 2026

New and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering.

New and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering.

Journal: Circulation research

Published: June 04, 2026

Trial of the Oral PCSK9 Inhibitor Enlicitide. Reply.

Trial of the Oral PCSK9 Inhibitor Enlicitide. Reply.

Journal: The New England journal of medicine

Published: May 06, 2026

Homozygous familial hypercholesterolemia: Will new LDL-C-lowering drugs replace lipoprotein apheresis?

Homozygous familial hypercholesterolemia: Will new LDL-C-lowering drugs replace lipoprotein apheresis?

Journal: European journal of preventive cardiology

Published: April 28, 2026

Real-world changes in lipid-lowering therapy use and LDL-C goal attainment in high and very high cardiovascular risk patients in the UK: a secondary analysis of the European SANTORINI study 1-year follow-up.

Real-world changes in lipid-lowering therapy use and LDL-C goal attainment in high and very high cardiovascular risk patients in the UK: a secondary analysis of the European SANTORINI study 1-year follow-up.

Journal: BMJ open

Published: April 24, 2026

Author Correction: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial.

Author Correction: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial.

Journal: Nature medicine

Published: April 17, 2026

European Medicines Agency versus Italian Medicines Agency indications for icosapent ethyl: a long and winding road.

European Medicines Agency versus Italian Medicines Agency indications for icosapent ethyl: a long and winding road.

Journal: Nutrition, metabolism, and cardiovascular diseases : NMCD

Published: April 11, 2026

CETP Renaissance with Obicetrapib.

CETP Renaissance with Obicetrapib.

Journal: Current atherosclerosis reports

Published: April 10, 2026

Showing 1-12 of 529

Last Updated: 09/26/2026